Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer.
Cancer. 2016; 122: 1312-1337
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
CA: a cancer journal for clinicians. 2018; 68: 394-424
Liver cancer: Regorafenib as second-line therapy in hepatocellular carcinoma.
Nat Rev Gastroenterol Hepatol. 2017; 14: 141-142
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet. 2017; 389: 56-66
Sorafenib in advanced hepatocellular carcinoma.
N Engl J Med. 2008; 359: 378-390
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Lancet. 2018; 391: 1163-1173
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.
N Engl J Med. 2018; 379: 54-63
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
The Lancet Oncology. 2019; 20: 282-296
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.
J Hepatol. 2017; 66: 545-551
Abou-Alfa GK, Chan SL, Furuse J, Galle PR, Kelley RK, Qin S, et al. A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study. 2018;36(15_suppl):TPS4144-TPS4144.
Yau T, Kang Y-K, Kim T-Y, El-Khoueiry AB, Santoro A, Sangro B, et al. Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. 2019;37(15_suppl):4012-4012.
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
Lancet. 2017; 389: 2492-2502
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
The Lancet Oncology. 2018; 19: 940-952
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
N Engl J Med. 2020; 382: 1894-1905
Yau T, Zagonel V, Santoro A, Acosta-Rivera M, Choo SP, Matilla A, et al. Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. Journal of Clinical Oncology. 2020;38(4_suppl):478-478.
The future of immune checkpoint therapy.
Science. 2015; 348: 56-61
Finn RS, Ryoo B-Y, Merle P, Kudo M, Bouattour M, Lim H-Y, et al. Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC). 2019;37(15_suppl):4004-4004.
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.
J Hepatol. 2013; 59: 81-88
Understanding the Cause and Consequence of Tumor Heterogeneity.
Trends in cancer. 2020; 6: 267-271
Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas.
Gut. 2019; 68: 2019-2031
Intratumor molecular and phenotypic diversity in hepatocellular carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research. 2015; 21: 1786-1788
Tumour evolution in hepatocellular carcinoma.
Nat Rev Gastroenterol Hepatol. 2020; 17: 139-152
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma.
Cancer Res. 2009; 69: 7385-7392
Common Molecular Subtypes Among Asian Hepatocellular Carcinoma and Cholangiocarcinoma.
Cancer Cell. 2017; 32 (): 57-70
Intratumor heterogeneity in hepatocellular carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research. 2015; 21: 1951-1961
A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells.
Nature medicine. 2006; 12: 410-416
Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning.
NatMed. 2003; 9: 416-423
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma.
Cell. 2017; 169 (): 1327-1341
Functional genomic complexity defines intratumor heterogeneity and tumor aggressiveness in liver cancer.
Scientific Reports. 2019; 9: 16930
Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model.
J Hepatol. 2017; 66: 75-85
Programmed cell death-1 blockade enhances response to stereotactic radiation in an orthotopic murine model of hepatocellular carcinoma.
Hepatology research : the official journal of the Japan Society of Hepatology. 2017; 47: 702-714
LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC).
Annals of Oncology. 2019; 30
Hallmarks of cancer: the next generation.
Cell. 2011; 144: 646-674
Unravelling biology and shifting paradigms in cancer with single-cell sequencing.
Nat Rev Cancer. 2017; 17: 557-569
Stem cell dynamics in homeostasis and cancer of the intestine.
Nat Rev Cancer. 2014; 14: 468-480
Tumor evolution: Linear, branching, neutral or punctuated?.
Biochim Biophys Acta Rev Cancer. 2017; 1867: 151-161
Massively parallel single-cell RNA-seq for marker-free decomposition of tissues into cell types.
Science. 2014; 343: 776-779
Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer.
Cancer Cell. 2019; 36 (): 418-430
Evolution of the cancer genome.
Nature reviews Genetics. 2012; 13: 795-806
The clonal evolution of tumor cell populations.
Science. 1976; 194: 23-28
Mutational heterogeneity in cancer and the search for new cancer-associated genes.
Nature. 2013; 499: 214-218
Extensive Clonal Branching Shapes the Evolutionary History of High-Risk Pediatric Cancers.
Cancer Res. 2020; 80: 1512-1523
Clonal genotype and population structure inference from single-cell tumor sequencing.
Nature methods. 2016; 13: 573-576
Tree inference for single-cell data.
Genome Biol. 2016; 17: 86
Cells of origin in cancer.
Nature. 2011; 469: 314-322
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution.
Cell. 2017; 171 (): 1259-1271
Cancer Evolution Constrained by the Immune Microenvironment.
Cell. 2017; 170: 825-827
Evolutionary dynamics of carcinogenesis and why targeted therapy does not work.
Nat Rev Cancer. 2012; 12: 487-493
Head SR, Komori HK, LaMere SA, Whisenant T, Van Nieuwerburgh F, Salomon DR, et al. Library construction for next-generation sequencing: overviews and challenges. BioTechniques. 2014;56(2):61-64, 66, 68, passim.
Zhang Q, He Y, Luo N, Patel SJ, Han Y, Gao R, et al. Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma. Cell. 2019;179(4):829-845.e820.
Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features.
Gastroenterology. 2017; 153: 812-826
The immune contexture of hepatocellular carcinoma predicts clinical outcome.
Scientific reports. 2018; 8: 5351
An Immune Atlas of Clear Cell Renal Cell Carcinoma.
Cell. 2017; 169 (): 736-749
Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses.
Cell. 2017; 169 (): 750-765
A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer.
Cell. 2019; 177 (): 1330-1345
Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing.
Nature medicine. 2018; 24: 978-985
Genetic basis for clinical response to CTLA-4 blockade in melanoma.
N Engl J Med. 2014; 371: 2189-2199
The application of single-cell sequencing technology in the diagnosis and treatment of hepatocellular carcinoma.
Ann Transl Med. 2019; 7: 790
Current Challenges in the Bioinformatics of Single Cell Genomics.
Frontiers in oncology. 2014; 4
Diverse modes of clonal evolution in HBV-related hepatocellular carcinoma revealed by single-cell genome sequencing.
Cell research. 2018; 28: 359-373
Single-cell and single-molecule epigenomics to uncover genome regulation at unprecedented resolution.
Nature genetics. 2019; 51: 19-25
From reads to insight: a hitchhiker’s guide to ATAC-seq data analysis.
Genome Biology. 2020; 21: 22
Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position.
Nature methods. 2013; 10: 1213-1218
Single-cell ATAC sequencing analysis: From data preprocessing to hypothesis generation.
Comput Struct Biotechnol J. 2020; 18: 1429-1439
Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution.
Nature genetics. 2016; 48: 1193-1203
Massively parallel single-cell chromatin landscapes of human immune cell development and intratumoral T cell exhaustion.
Nature biotechnology. 2019; 37: 925-936
Comparative Analysis of Single-Cell RNA Sequencing Methods.
Molecular cell. 2017; 65 (): 631-643
Smart-seq2 for sensitive full-length transcriptome profiling in single cells.
Nature methods. 2013; 10: 1096-1098
Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets.
Cell. 2015; 161: 1202-1214
Single cell analysis reveals cancer stem cell heterogeneity in hepatocellular carcinoma.
Single-cell transcriptomics reveals the landscape of intra-tumoral heterogeneity and stemness-related subpopulations in liver cancer.
Cancer letters. 2019; 459: 176-185
Functional and genetic deconstruction of the cellular origin in liver cancer.
Nat Rev Cancer. 2015; 15: 653-667
Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer.
Cell. 2017; 171 (): 1611-1624
Finn RS, Ducreux M, Qin S, Galle PR, Zhu AX, Ikeda M, et al. IMbrave150: A randomized phase III study of 1L atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma. Journal of Clinical Oncology. 2018;36(15_suppl):TPS4141-TPS4141.
Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.
Int J Cancer. 2014; 134: 319-331
Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells.
Hepatology. 2013; 57: 2358-2368
Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma.
Molecular therapy : the journal of the American Society of Gene Therapy. 2019; 27: 1483-1494
Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing.
Cell. 2017; 169 (): 1342-1356
Genetic and phenotypic difference in CD8(+) T cell exhaustion between chronic hepatitis B infection and hepatocellular carcinoma.
J Med Genet. 2019; 56: 18-21
PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients.
Int J Cancer. 2011; 128: 887-896
Molecular signature of CD8+ T cell exhaustion during chronic viral infection.
Immunity. 2007; 27: 670-684
Inhibitory Receptors Beyond T Cell Exhaustion.
Front Immunol. 2015; 6: 310
The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells.
Nature biotechnology. 2014; 32: 381-386
The single-cell transcriptional landscape of mammalian organogenesis.
Nature. 2019; 566: 496-502
Campbell K, Ponting CP, Webber C. Laplacian eigenmaps and principal curves for high resolution pseudotemporal ordering of single-cell RNA-seq profiles. 2015:027219.
Cannoodt R, Saelens W, Sichien D, Tavernier S, Janssens S, Guilliams M, et al. SCORPIUS improves trajectory inference and identifies novel modules in dendritic cell development. 2016:079509.
TSCAN: Pseudo-time reconstruction and evaluation in single-cell RNA-seq analysis.
Nucleic acids research. 2016; 44: e117
Linking T-cell receptor sequence to functional phenotype at the single-cell level.
Nature biotechnology. 2014; 32: 684-692
Multi-omics study revealing the complexity and spatial heterogeneity of tumor-infiltrating lymphocytes in primary liver carcinoma.
Oncotarget. 2017; 8: 34844-34857
The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma.
Cancer immunology, immunotherapy : CII. 2019; 68: 599-608
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.
N Engl J Med. 2016; 375: 2255-2262
In situ tumor ablation creates an antigen source for the generation of antitumor immunity.
Cancer Res. 2004; 64: 4024-4029
Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity.
British journal of cancer. 2006; 95: 896-905
Combined locoregional-immunotherapy for liver cancer.
J Hepatol. 2019; 70: 999-1007
Effects of microwave ablation on T-cell subsets and cytokines of patients with hepatocellular carcinoma.
Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy. 2017; 26: 207-211
A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells.
Gastroenterology. 2008; 135: 234-243
Increase in CD14+HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. Cancer immunology, immunotherapy.
CII. 2013; 62: 1421-1430
Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes.
International journal of oncology. 2012; 40: 63-70
Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma.
Gut. 2019; 68: 335-346
Immunogenicity of anthracyclines: moving towards more personalized medicine.
Trends in molecular medicine. 2008; 14: 141-151
Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma.
Hepatology. 2013; 57: 1448-1457
Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma.
Gut. 2019; 68: 916-927
Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis.
Scientific reports. 2015; 5: 15179
Activated and Exhausted MAIT Cells Foster Disease Progression and Indicate Poor Outcome in Hepatocellular Carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research. 2019; 25: 3304-3316
MAIT cells are licensed through granzyme exchange to kill bacterially sensitized targets.
Mucosal Immunol. 2015; 8: 429-440
Spatiotemporal dynamics of molecular pathology in amyotrophic lateral sclerosis.
Science (New York, NY). 2019; 364: 89-93
Intratumoral heterogeneity and clonal evolution in liver cancer.
Nature communications. 2020; 11: 291
Molecular and genetic properties of tumors associated with local immune cytolytic activity.
Cell. 2015; 160: 48-61
Tracking the Evolution of Non-Small-Cell Lung Cancer.
N Engl J Med. 2017; 376: 2109-2121
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Science. 2015; 348: 124-128
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Science. 2017; 357: 409-413
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.
Science. 2016; 351: 1463-1469
Cancer genomic research at the crossroads: realizing the changing genetic landscape as intratumoral spatial and temporal heterogeneity becomes a confounding factor.
Cancer Cell Int. 2014; 14: 115
High-density single cell mRNA sequencing to characterize circulating tumor cells in hepatocellular carcinoma.
Scientific reports. 2018; 8: 11570
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
N Engl J Med. 2018; 378: 1277-1290
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
N Engl J Med. 2017; 377: 1345-1356
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
N Engl J Med. 2019; 381: 2020-2031
Kelley RK, Abou-Alfa GK, Bendell JC, Kim T-Y, Borad MJ, Yong W-P, et al. Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses. 2017;35(15_suppl):4073-4073.
Translational Considerations to Improve Response and Overcome Therapy Resistance in Immunotherapy for Hepatocellular Carcinoma.
Cancers. 2020; 12
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
Nature. 2014; 515: 563-567
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016; 34: 4102-4109
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
N Engl J Med. 2012; 366: 2443-2454
Low Levels of Microsatellite Instability at Simple Repeated Sequences Commonly Occur in Human Hepatocellular Carcinoma.
Cancer genomics & proteomics. 2017; 14: 329-339
Joint profiling of chromatin accessibility and gene expression in thousands of single cells.
Science (New York, NY). 2018; 361: 1380-1385
Moffitt JR, Bambah-Mukku D, Eichhorn SW, Vaughn E, Shekhar K, Perez JD, et al. Molecular, spatial, and functional single-cell profiling of the hypothalamic preoptic region. Science (New York, NY). 2018;362(6416):eaau5324.
Parallel single-cell sequencing links transcriptional and epigenetic heterogeneity.
Nature methods. 2016; 13: 229-232
Visualization and analysis of gene expression in tissue sections by spatial transcriptomics.
Science (New York, NY). 2016; 353: 78-82
Translating insights into tumor evolution to clinical practice: promises and challenges.
Genome Med. 2019; 11: 20
Cancer genomics: one cell at a time.
Genome Biol. 2014; 15: 452
The functional plasticity of T cell subsets.
Nature Reviews Immunology. 2009; 9: 811-816
The functional plasticity of T cell subsets.
Nature Reviews Immunology. 2009; 9: 811-816
Floudas CS, Xie C, Brar G, Morelli MP, Fioravanti S, Walker M, et al. Combined immune checkpoint inhibition (ICI) with tremelimumab and durvalumab in patients with advanced hepatocellular carcinoma (HCC) or biliary tract carcinomas (BTC). Journal of Clinical Oncology. 2019;37(4_suppl):336-336.
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
N Engl J Med. 2020; 382: 1894-1905
CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: From bench to bedside.
Oncoimmunology. 2016; 5e1251539
Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research. 2014; 20: 6418-6428
Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma.
Molecular therapy : the journal of the American Society of Gene Therapy. 2018; 26: 366-378
Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma.
Front Immunol. 2016; 7: 690
Determining cell type abundance and expression from bulk tissues with digital cytometry.
Nature biotechnology. 2019; 37: 773-782
Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma.
Scientific reports. 2018; 8: 6220